Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Sales (2019 - 2025)

Keros Therapeutics filings provide 7 years of Return on Sales readings, the most recent being 0.41% for Q4 2025.

  • On a quarterly basis, Return on Sales fell 131.0% to 0.41% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.0%, a 1561.0% decrease, with the full-year FY2025 number at 0.0%, changed N/A from a year prior.
  • Return on Sales hit 0.41% in Q4 2025 for Keros Therapeutics, down from 0.01% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.91% in Q4 2024 to a low of 54.1% in Q3 2023.
  • Median Return on Sales over the past 5 years was 0.06% (2022), compared with a mean of 5.26%.
  • Biggest five-year swings in Return on Sales: crashed -5408bps in 2023 and later soared 5274bps in 2024.
  • Keros Therapeutics' Return on Sales stood at 0.0% in 2021, then tumbled by -1400bps to 0.06% in 2022, then tumbled by -5486bps to 3.25% in 2023, then skyrocketed by 128bps to 0.91% in 2024, then plummeted by -145bps to 0.41% in 2025.
  • The last three reported values for Return on Sales were 0.41% (Q4 2025), 0.01% (Q3 2025), and 0.02% (Q2 2025) per Business Quant data.